Ambrx Biopharma Inc. (AMAM) concluded trading on Thursady at a closing price of $27.93, with 7.75 million shares of worth about $216.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 107.81% during that period and on Thursady the price saw a gain of about 0.83%. Currently the company’s common shares owned by public are about 63.29M shares, out of which, 55.08M shares are available for trading.
Stock saw a price change of 0.58% in past 5 days and over the past one month there was a price change of 0.68%. Year-to-date (YTD), AMAM shares are showing a performance of 96.14% which increased to 513.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.64 but also hit the highest price of $28.15 during that period. The average intraday trading volume for Ambrx Biopharma Inc. shares is 1.75 million. The stock is currently trading 0.59% above its 20-day simple moving average (SMA20), while that difference is up 24.20% for SMA50 and it goes to 83.65% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ambrx Biopharma Inc. (NASDAQ: AMAM) currently have 63.29M outstanding shares and institutions hold larger chunk of about 92.16% of that.
The stock has a current market capitalization of $1.77B and its 3Y-monthly beta is at -1.93. It has posted earnings per share of -$2.02 in the same period. It has Quick Ratio of 13.28 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMAM, volatility over the week remained 0.49% while standing at 0.33% over the month.
Analysts are in expectations that Ambrx Biopharma Inc. (AMAM) stock would likely to be making an EPS of -$0.39 in the current quarter, while forecast for next quarter EPS is -$0.4 and it is -$1.61 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.45 which is -$0.34 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -375.86% while it is estimated to decrease by -16.49% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on September 25, 2023 offering a Mkt outperform rating for the stock and assigned a target price of $15 to it. Coverage by BTIG Research stated Ambrx Biopharma Inc. (AMAM) stock as a Buy in their note to investors on September 12, 2023, suggesting a price target of $26 for the stock. On July 31, 2023, RBC Capital Mkts Initiated their recommendations, while on June 14, 2023, B. Riley Securities Initiated their ratings for the stock with a price target of $26. Stock get an Outperform rating from Oppenheimer on June 02, 2023.
